Pages

Sunday, March 31, 2013

[LST] SC rejects patent protection for Novartis cancer drug Glivec - The Hindu: Mobile Edition

Yay :D !


http://m.thehindu.com/news/national/sc-rejects-patent-protection-for-novartis-cancer-drug-glivec/article4569056.ece/?maneref=http%3A%2F%2Ft.co%2F7vSHn1aGHc


SC rejects patent protection for Novartis cancer drug Glivec
25 minutes ago , By IANS

Novartis had been fighting a prolonged legal case for the patent of Glivec, a cost effective drug. File Photo: P.V. Sivakumar
The Supreme Court on Monday dismissed Swiss pharmaceutical chain Novartis AG's petition seeking patent protection for its anti-cancer drug, Glivec (Imatinib mesylate).
The apex court bench of Justices Aftab Alam and Ranjana Prakash Desai dismissed with cost Novartis' plea challenging the Intellectual Property Appellate Board's decision declining the plea for patent of the drug that is used in the treatment of chronic myeloid leukaemia and malignant gastrointestinal stromal tumours.
The patent right for the drug was denied to Novartis in 2006 by the Chennai-based Intellectual Property Appellate Board.
The legal battle for the patent of the blood cancer drug is being closely watched by international pharmaceutical firms. Novartis had been fighting a prolonged legal case for the patent of Glivec, a cost effective drug.
Winning such a patent would have barred Indian firms from manufacturing generic drugs.

--
"To those who believe in resistance, who live between hope and impatience and have learned the perils of being unreasonable. To those who understand enough
to be afraid and yet retain their fury."


Sent on my BlackBerry® from Vodafone

--
You received this message because you are subscribed to the Google Groups "LST-LAW SCHOOL TUTORIALS" group.
To unsubscribe from this group and stop receiving emails from it, send an email to clat-11+unsubscribe@googlegroups.com.
For more options, visit https://groups.google.com/groups/opt_out.

0 comments:

Post a Comment